肌少症性肥胖是一种肌肉减少症(简称肌少症)与肥胖共存的临床状态。 在肌少症和肥胖共存的状态下,身体的 瘦体组织与脂肪含量失衡,其与不良的临床结局相关。 肌少症和肥胖对健康都有着独立的不良影响,两者同时并存而产生的 协同作用导致代谢紊乱加重,使肌少症性肥胖所带来的健康问题远比单纯的肌少症或单纯肥胖更加严重。 而早期有效的干 预措施,可以预防、治疗、延缓肌少症性肥胖的进程,因此早期的筛查、诊断和治疗尤为重要。 对肌少症性肥胖的治疗措施主 要包括营养和运动干预,新型的药物治疗或肠道菌群治疗对肌少症性肥胖也有一定的作用。 近年来,关于肌少症性肥胖的研 究已取得了一定的进展,欧洲肠外肠内营养学会及欧洲肥胖研究协会已发布了诊断标准,首次明确了其诊断,肌少症性肥胖 的发病机制,代谢障碍和炎症间复杂的相互作用也进一步被揭示,但目前仍没有治疗肌少症性肥胖的特效方法。 本文就肌少 症性肥胖的诊断标准、发病分子机制和治疗进展进行综述,为肌少症性肥胖的防治和临床研究提供参考。

Sarcopenic obesity is a clinical state in which the co - existence of obesity and sarcopenia. In the co - existence of sarcopenia and obesity the lean body mass is unbalanced with the fat content. Which is associated with adverse clinical outcomes. Both sarcopenia and obesity have independent adverse effects on health and the synergistic effect of both leads to increased metabolic disorders making the health problems brought by sarcopenia obesity far more serious than that of sarcopenia or obesity alone. Early and effective intervention measures can prevent treat and delay the progression of sarcopenic obesity. Therefore early screening diagnosis and treatment are particularly important. The treatment measures for sarcopenic obesity mainly include nutrition and exercise intervention and new drug therapy or intestinal flora therapy also have a certain effect on sarcopenic obesity. In recent years research on sarcopenic obesity has made certain progress. The European Society for Clinical Nutrition and Metabolism and the European Association for Obesity Research have published diagnostic criteria to clarify their diagnosis for the first time the pathogenesis of sarcopenic obesity and the complex interaction between metabolic disorders and inflammation have been further revealed but there is still no specific treatment for sarcopenic obesity. This paper reviews the diagnostic criteria molecular mechanisms and treatment progress of sarcopenic obesity providing reference for the prevention treatment and clinical research of sarcopenic obesity.